Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 47

Sort by

Sort Order Select

Journal Articles

UM171 Cord Blood Transplantation for TP53 Mutated and EVI1 Rearranged Myelodysplasia/Acute Myeloid Leukemia

Sandra Cohen, Nadia M. Bambace, Lea Bernard, Imran Ahmad, Jean Roy, Sylvie Lachance, Jean-Sebastien Delisle, Thomas L. Kiss, Denis-Claude Roy, Olivier Veilleux, Guy Sauvageau

Blood (2024) 144 (Supplement 1): 1502.

https://doi.org/10.1182/blood-2024-211972

Published: 2024

Journal Articles

Long Term Follow up of UM171 Expanded Cord Blood Transplantation Patients Does Not Reveal Any Late Toxicity

Sandra Cohen, Nadia M. Bambace, Lea Bernard, Imran Ahmad, Jean Roy, Sylvie Lachance, Jean-Sebastien Delisle, Thomas L. Kiss, Denis-Claude Roy, Olivier Veilleux, Guy Sauvageau

Blood (2024) 144 (Supplement 1): 4916.

https://doi.org/10.1182/blood-2024-194132

Published: 2024

Journal Articles

Allogeneic Hematopoietic Stem Cell Transplant for B-Cell Lymphomas in the Era of Novel Cellular Therapies: Experience from a Tertiary Canadian Center

Mathias Castonguay, Jean-Sébastien Claveau, Jean Roy, Sandra Cohen, Sylvie Lachance, Imran Ahmad, Nadia M. Bambace, Lea Bernard, Jean-Sebastien Delisle, Thomas L. Kiss, Isabelle Fleury, Luigina Mollica, Denis-Claude Roy, Guy Sauvageau, Olivier Veilleux

Blood (2024) 144 (Supplement 1): 7446.

https://doi.org/10.1182/blood-2024-210718

Published: 2024

Journal Articles

UM171 Expanded Cord Blood Transplantation Outcomes Compare Favorably to All Different Stem Cell Sources: An EBMT Registry Case-Control Analysis

Blood (2023) 142 (Supplement 1): 4977.

https://doi.org/10.1182/blood-2023-173727

Published: 2023

Journal Articles

Infusion of UM171-Expanded Cord Blood Led to Excellent Survival in Patients with High-Risk Leukemias: Results from Two Independent Phase II Studies

Filippo Milano, Guy Sauvageau, Gabrielle Thauvette, Nadia M. Bambace, Lea Bernard, Imran Ahmad, Jean Roy, Laura C Roberts, Laurel Thur, Jenna B Pedersen, Ann Dahlberg, Sandra Cohen

Blood (2023) 142 (Supplement 1): 1040.

https://doi.org/10.1182/blood-2023-187446

Published: 2023

Journal Articles

Prognosis of Progressive Follicular Lymphoma within 24 Months of First-Line Therapy Is Not Influenced By the Initial Regimen Intensity

Camille Gauvin, Imran Ahmad, Luigina Mollica, Sandra Cohen, Olivier Veilleux, Sylvie Lachance, Isabelle Fleury

Blood (2023) 142 (Supplement 1): 6150.

https://doi.org/10.1182/blood-2023-183021

Published: 2023

Journal Articles

The EBMT Disease Risk Stratification System (DRSS) Allows Prediction of Relapse after Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndrome

Yasmine Kadri, Michelle Phan, Nadia Bambace, Léa Bernard, Sandra Cohen, Jean-Sébastien Delisle, Thomas L. Kiss, Sylvia Lachance, Denis-Claude Roy, Jean Roy, Guy Sauvageau, Olivier Veilleux, Imran Ahmad

Blood (2022) 140 (Supplement 1): 7759–7760.

https://doi.org/10.1182/blood-2022-157107

Published: 2022

Journal Articles

Improved Outcomes of UM171-Expanded Cord Blood Transplantation Compared with Other Graft Sources: Real World Evidence

Sandra Cohen, Nadia M. Bambace, Imran Ahmad, Linda J. Burns, Jean Roy, Silvy Lachance, Léa Bernard, Jean-Sébastien Delisle, Denis-Claude Roy, Thomas L. Kiss, Olivier Veilleux, Mei-Jie Zhang, Xiao-Ying Tang, Guy Sauvageau

Blood (2022) 140 (Supplement 1): 1610–1612.

https://doi.org/10.1182/blood-2022-160417

Published: 2022

Journal Articles

Geographical CAR-T Unmet Needs for Patients with Large B-Cell Lymphoma in the Province of Quebec

Maria Murphy, Mathilde Fromentin, Julie Campeau, Michael Sebag, Félix Couture, Jean-François Larouche, Christopher Lemieux, Silvy Lachance, Sandra Cohen, Luigina Mollica, Olivier Veilleux, Isabelle Fleury

Blood (2022) 140 (Supplement 1): 13228–13229.

https://doi.org/10.1182/blood-2022-156473

Published: 2022

Journal Articles

Ex Vivo Generation and Infusion of Anti-Minor Histocompatibility Antigen Expanded T Cells for Patients Who Relapse after Allogeneic HLA-Matched Stem Cell Transplantation

Blood (2022) 140 (Supplement 1): 1601–1603.

https://doi.org/10.1182/blood-2022-170147

Published: 2022

Journal Articles

UM171-Expanded Cord Blood Transplants Support Robust T-Cell Reconstitution with Low Rates of Severe Infections

Blood (2020) 136 (Supplement 1): 36–37.

https://doi.org/10.1182/blood-2020-139598

Published: 2020

Journal Articles

UM171 Modified Cord Blood Achieves Excellent Survival and Disease Control after 2 Years of Follow-up in High and Very High Risk Malignancies

Sandra Cohen, MD FRCP(C), Jean Roy, MD, Jean-Sébastien Delisle, MD PhD, Nadia M. Bambace, MD, Imran Ahmad, MD, Silvy Lachance, MD FRCP, Léa Bernard, MD, Frederic Barabe, MD, Thomas L. Kiss, MD, Lambert Busque, MD, Denis-Claude Roy, MD, Filippo Milano, MD PhD, Guy Sauvageau, MD PhD

Blood (2019) 134 (Supplement_1): 3245.

https://doi.org/10.1182/blood-2019-121698

Published: 2019

Journal Articles

Single UM171 Expanded Cord Blood Permits Transplantation of Better HLA Matched Cords with Excellent Gvhd Relapse Free Survival

Blood (2018) 132 (Supplement 1): 4658.

https://doi.org/10.1182/blood-2018-99-110188

Published: 2018

Journal Articles

Minimal Residual Disease Evaluation Using 8-Color Flow Cytometry Predicts Risk of Relapse in High-Risk and/or Young Myeloma Patients Who Receive Bortezomib Consolidation after Frontline Tandem Transplantation

Richard Leblanc, MD FRCPC, Imran Ahmad, MD MPH, Rafik Terra, PhD, Séverine Landais, PhD, Céline Nkoue, MD, Michael Sebag, MD PhD, Émilie Lemieux Blanchard, MD FRCPC, Nadia M. Bambace, MD, Léa Bernard, MD, Sandra Cohen, MD FRCP(C), Jean-Sébastien Delisle, MD PhD, Thomas L. Kiss, MD, Silvy Lachance, MD FRCP, Denis-Claude Roy, MD, Guy Sauvageau, MD, PhD, Jean Roy, MD

Blood (2018) 132 (Supplement 1): 4666.

https://doi.org/10.1182/blood-2018-99-112313

Published: 2018

Journal Articles

Single UM171 Expanded Cord Blood Transplant Is Feasible, Safe, and Permits Transplantation of Better HLA Matched Cords with Very Low Transplant Related Mortality

Sandra Cohen, MD, Jean Roy, MD, Silvy Lachance, MDFRCPC, Anne Marinier, PhD, Denis-Claude Roy, MD, Jean-Sébastien Delisle, MD PhD, Lambert Busque, MD, Pierre Caudrelier, MD, Fannie Larochelle, Philippe Bouchard, BPharm, Jean Roy, MD, Nadia M. Bambace, MD, Léa Bernard, MD, Thomas L Kiss, MD, Sébastien Lemieux, PhD, Peter W. Zandstra, PhD, Guy Sauvageau, MD, PhD

Blood (2017) 130 (Supplement 1): 658.

https://doi.org/10.1182/blood.V130.Suppl_1.658.658

Published: 2017

Journal Articles

Impact of Carmustine (BCNU) Substitution for Bendamustine in the Conditioning Regimen Prior to Autologous Hematopoietic Cell Transplantation for the Treatment of Lymphoma

Josie-Anne Boisjoly, MD, Philippe Bouchard, BPharm, Sandra Cohen, MD FRCP(C), Imran Ahmad, MD, Nadia M. Bambace, MD, Léa Bernard, MD, Jean-Sébastien Delisle, MD PhD, Thomas L Kiss, MD, Denis-Claude Roy, MD, Guy Sauvageau, MD, PhD, Jean Roy, MD, Silvy Lachance, MDFRCPC

Blood (2017) 130 (Supplement 1): 2022.

https://doi.org/10.1182/blood.V130.Suppl_1.2022.2022

Published: 2017

Journal Articles

Bortezomib Consolidation after Nonmyeloablative Allogeneic Transplant Is Safe and Leads to a High Incidence of Immunophenotypic Complete Response in High-Risk or Young Myeloma Patients

Richard LeBlanc, MDFRCPC, Imran Ahmad, MD M.Sc., Rafik Terra, PhD, Séverine Landais, PhD, Michael Sebag, MD PhD, Emilie Lemieux-Blanchard, MD, Nadia M. Bambace, MD, Léa Bernard, MD, Sandra Cohen, MD, Jean-Sébastien Delisle, MD PhD, Thomas Kiss, MD, Silvy Lachance, MDFRCPC, Denis-Claude Roy, MD, Guy Sauvageau, MD PhD, Jean Roy, MD

Blood (2017) 130 (Supplement 1): 4556.

https://doi.org/10.1182/blood.V130.Suppl_1.4556.4556

Published: 2017

Journal Articles

Bortezomib Consolidation after Nonmyeloablative Allogeneic Stem Cell Transplantation Leads to a High Incidence of Immunophenotypic Complete Response in Young and/or High-Risk Multiple Myeloma Patients

Richard LeBlanc, MD, Imran Ahmad, MD, Rafik Terra, PhD, Séverine Landais, PhD, Michael Sebag, MD PhD, Emilie Lemieux-Blanchard, MD, Nadia M. Bambace, MD, Lea Bernard, MD, Sandra Cohen, MD, Jean-Sebastien Delisle, MD PhD, Thomas Kiss, MD, Silvy Lachance, MD, Denis-Claude Roy, MD, Guy Sauvageau, MD PhD, Jean Roy, MD

Blood (2016) 128 (22): 2306.

https://doi.org/10.1182/blood.V128.22.2306.2306

Published: 2016

Journal Articles

Clinical Retrospective Analysis of 42 Patients with Primary Bone Lymphoma Treated at Maisonneuve-Rosemont Hospital

Katie Guo, MD, Melissa Boileau, MD, Bernard Fortin, MD FRCPC, Francine Aubin, MD FRCPC, Tony Petrella, MD, Marc Isler, MD FRCSC, Sophie Mottard, MD FRCSC, Sandra Cohen, MD, Luigina Mollica, MD PhD, Julie Beaudet, MD FRCPC, Isabelle Fleury, MD MSc, FRCPC

Blood (2016) 128 (22): 5404.

https://doi.org/10.1182/blood.V128.22.5404.5404

Published: 2016

Journal Articles

Atypical Chronic Lymphocytic Leukemia with CD200 Expression Shares Similar Outcomes to Classical Chronic Lymphocytic Leukemia

Zoe Mongeau-Marceau, MD, Sandra Cohen, MD, Luigina Mollica, MD PhD, Richard LeBlanc, MD, Bernard Fortin, MD FRCPC, Rafik Terra, PhD, Isabelle Fleury, MD MSc, FRCPC

Blood (2016) 128 (22): 5572.

https://doi.org/10.1182/blood.V128.22.5572.5572

Published: 2016

NARROW

UM171 Cord Blood Transplantation for TP53 Mutated and EVI1 Rearranged Myelodysplasia/Acute Myeloid Leukemia

Long Term Follow up of UM171 Expanded Cord Blood Transplantation Patients Does Not Reveal Any Late Toxicity

Allogeneic Hematopoietic Stem Cell Transplant for B-Cell Lymphomas in the Era of Novel Cellular Therapies: Experience from a Tertiary Canadian Center

UM171 Expanded Cord Blood Transplantation Outcomes Compare Favorably to All Different Stem Cell Sources: An EBMT Registry Case-Control Analysis

Infusion of UM171-Expanded Cord Blood Led to Excellent Survival in Patients with High-Risk Leukemias: Results from Two Independent Phase II Studies

Prognosis of Progressive Follicular Lymphoma within 24 Months of First-Line Therapy Is Not Influenced By the Initial Regimen Intensity

The EBMT Disease Risk Stratification System (DRSS) Allows Prediction of Relapse after Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndrome

Improved Outcomes of UM171-Expanded Cord Blood Transplantation Compared with Other Graft Sources: Real World Evidence

Geographical CAR-T Unmet Needs for Patients with Large B-Cell Lymphoma in the Province of Quebec

Ex Vivo Generation and Infusion of Anti-Minor Histocompatibility Antigen Expanded T Cells for Patients Who Relapse after Allogeneic HLA-Matched Stem Cell Transplantation

UM171-Expanded Cord Blood Transplants Support Robust T-Cell Reconstitution with Low Rates of Severe Infections

UM171 Modified Cord Blood Achieves Excellent Survival and Disease Control after 2 Years of Follow-up in High and Very High Risk Malignancies

Single UM171 Expanded Cord Blood Permits Transplantation of Better HLA Matched Cords with Excellent Gvhd Relapse Free Survival

Minimal Residual Disease Evaluation Using 8-Color Flow Cytometry Predicts Risk of Relapse in High-Risk and/or Young Myeloma Patients Who Receive Bortezomib Consolidation after Frontline Tandem Transplantation

Single UM171 Expanded Cord Blood Transplant Is Feasible, Safe, and Permits Transplantation of Better HLA Matched Cords with Very Low Transplant Related Mortality

Impact of Carmustine (BCNU) Substitution for Bendamustine in the Conditioning Regimen Prior to Autologous Hematopoietic Cell Transplantation for the Treatment of Lymphoma

Bortezomib Consolidation after Nonmyeloablative Allogeneic Transplant Is Safe and Leads to a High Incidence of Immunophenotypic Complete Response in High-Risk or Young Myeloma Patients

Bortezomib Consolidation after Nonmyeloablative Allogeneic Stem Cell Transplantation Leads to a High Incidence of Immunophenotypic Complete Response in Young and/or High-Risk Multiple Myeloma Patients

Clinical Retrospective Analysis of 42 Patients with Primary Bone Lymphoma Treated at Maisonneuve-Rosemont Hospital

Atypical Chronic Lymphocytic Leukemia with CD200 Expression Shares Similar Outcomes to Classical Chronic Lymphocytic Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only